Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

About this update from Allogene Therapeutics, Inc.

[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QCsYA1reL6jmKogB1ZpqzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":83,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.","length":521,"tagName":"p"},{"type":"text","content":"Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.","length":254,"tagName":"p"},{"type":"text","content":"Conference Call RegistrationIf you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.","length":237,"tagName":"p"},{"type":"text","content":"About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CA...

More updates from Allogene Therapeutics, Inc.